The C-C Chemokine Receptor Type 4 Is an Immunomodulatory Target of Hydroxychloroquine

The C-C Chemokine Receptor Type 4 Is an Immunomodulatory Target of Hydroxychloroquine

The emergence of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19) in China, reported to the World Health Organization on December 31, 2019, has led to a large global pandemic and is a major public health issue. As a result, there are more than 200 clinical trials of COVID-19...

Full description

Bibliographic Details
Main Authors: Tyler C. Beck, Kyle R. Beck, Calvin B. Holloway, Richard A. Hemings, Thomas A. Dix, Russell A. Norris
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Pharmacology
Subjects:
COVID-19
hydroxychloroquine
CCR4
SARS-CoV-2
immunomodulation
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.01253/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.01253/full

Similar Items